Merck's AIDS 2026 HIV Data Won't Move MRK Alone-But It Shows How Much Extra Cash the HIV Unit Could Unlock

AIDS 2026 is a pipeline credibility test for Merck, not a quarter-saver

Merck does not need HIV data to rescue the quarter. The first-quarter business was still sizable, with $16.3 billion in total worldwide sales, including KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion and Animal Health Sales Were $1.8 Billion. That is an established cash engine. The real question is whether HIV can become a more credible recurring growth stream alongside that base.

At AIDS 2026, Merck is trying to show what comes after the recent FDA approval of IDVYNSO. The company said it is emphasizing once-weekly oral treatments in combination with islatravir. That makes this a pipeline-credibility event more than an earnings event.

The core question: can once-weekly HIV treatment match daily outcomes?

AIDS 2026 is a large meeting, but not every announcement matters for Merck investors. The conference featured about 7,500 delegates and 2,400 posters. For MRK, the signal is narrower: can a once-weekly oral regimen offer meaningful convenience without trading away viral suppression or safety?

That is why the main audience is adults with virologically-suppressed HIV-1. The commercial logic only works if patients who are already controlled on daily therapy are willing to switch and stay suppressed on a simpler schedule.

The key data points are the Phase 3 Week 48 readouts

The most important evidence is the Week 48 efficacy and safety data from the Phase 3 ISLEND-1 and ISLEND-2 trials. Those studies compare once-weekly islatravir plus lenacapavir with daily standard therapy, which is why they matter more than the newer or smaller signals.

The Phase 2b Week 24 data for islatravir plus ulonivirine are supportive, not decisive. They help show platform breadth, but they are early enough that they should not carry the investment case on their own.

What investors actually need to see for the cash-flow story to improve

Investors do not need a perfect headline. They need evidence that the weekly regimen is both clinically credible and commercially usable. The main checkpoints are:

• Durability: viral suppression holds through the full Week 48 efficacy and safety data assessment period.
• Safety: the weekly regimen does not introduce a meaningfully worse tolerability profile.
• Comparator relevance: results are measured against established daily therapies, not a weak benchmark.
• Commercial plausibility: convenience improvements are meaningful enough to matter in real-world prescribing and guideline discussions.

If those boxes are checked, the data say more than 'interesting.' They suggest Merck's HIV portfolio could become a broader platform rather than a one-product story.

Near-term catalyst: conference data, then a direct investor update

The timing is tight. Merck is presenting HIV data at AIDS 2026 and has scheduled a virtual investor event on August 3, 2026. That gives investors a short window to judge whether the data are merely academically interesting or actually expand the HIV unit's earning power.

The practical setup: own Merck for the core franchise; treat HIV as upside

The cleaner approach is to view Merck as a broader biopharma franchise first and an HIV call option second. The stock already reflects a 55.54% one-year total shareholder return and sits near a fair-value estimate of US$129.74, so this is not a turnaround thesis. It is a question of whether an already large business has another credible growth layer ahead.

Merck still has established engines to lean on, including continued strength in oncology and animal health. If that base remains solid, HIV does not need to save the quarter. It just needs to make the next cash stream look durable enough to matter.

Bull case vs. bear case

Bulls do not need a spectacle. They need ISLEND-1 and ISLEND-2 to show that once-weekly treatment can work as well as daily therapy over 48 weeks. If that happens, Merck's HIV portfolio starts to look more like a repeatable growth segment than a post-approval publicity event.

Bears have a reasonable counter: when shares have already rallied sharply and trade near fair value, merely 'good' data may not be enough to trigger a rerating. In that setup, the market may acknowledge the results and move on.

What to watch next

Use the AIDS presentations as the first read on management's ability to turn trial data into commercial confidence. The next check is whether follow-through on earnings and investor updates strengthens that story or leaves HIV looking more like science than a near-term cash generator.